Synthesis and Molecular Modeling of 1-Phenyl-1,2,3,4-tetrahydroisoquinolines and Related 5,6,8,9-Tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 Dopamine Antagonists

Journal of Medicinal Chemistry

Volumn 37, Issue 25, 1994, Pages 4317-4328

  Minor, Deborah L ^a   Wyrick, Steven D ^a   Charifson, Paul S ^a   Watts, Val J ^b   Mailman, Richard B ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4 TETRAHYDRO 1 PHENYLISOQUINOLINE DERIVATIVE; 6 BROMO 1,2,3,4 TETRAHYDRO 7 HYDROXY 2 METHYL 1 PHENYLISOQUINOLINE; 6 CHLORO 1,2,3,4 TETRAHYDRO 7 HYDROXY 2 METHYL 1 PHENYLISOQUINOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG SYNTHESIS; NEUROTRANSMISSION; NONHUMAN; QUANTITATIVE DIAGNOSIS; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMAL; BINDING, COMPETITIVE; CELL MEMBRANE; CHEMISTRY, PHYSICAL; COMPARATIVE STUDY; COMPUTER SIMULATION; CORPUS STRIATUM; ELECTROCHEMISTRY; ISOQUINOLINES; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; REGRESSION ANALYSIS; SCH-23390; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028555339     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00051a008     Document Type: Article

References (36)

1. Carlsson, A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu. Rev. Neurosci. 1987, 10, 19-40.
2. Garau, L.; Govoni, S.; Stefanini, E.; Trabucchi, M.; Spano, P. F. Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci. 1978, 23, 1745-1750.
3. Kebabian, J.; Caine, D. Multiple Receptors for Dopamine. Nature 1979, 277, 93-96.
4. Creese, I.; Leff, S. Dopamine Receptors: A Classification. J. Clin. Psychopharmacol. 1982, 2, 329-335.
5. Snyder, S. The Dopamine Hypothesis of Schizophrenia: Focus on the Dopamine Receptor. Am. J. Psychiatry 1976, 133, 197-202.
6. Lauduron, P. Commentary: Dopamine-sensitive Adenylate Cyclase as a Receptor Site. In Dopamine Receptors; Kaiser, C., Kebabian, J., Eds.; American Chemical Society: Washington, D.C., 1983, p 22.
7. Iorio, L. C.; Barnett, A.; Leitz, F. H.; Houser, V. P.; Korduba, C. SCH23390, A Potential Benzazepine Antipsychotic with Unique Interactions on Dopaminergic Systems. J. Pharmacol. Exp. Ther. 1983, 226, 462-468.
8. Mailman, R. B.; Schulz, D. W.; Lewis, M. H.; Staples, L.; Rollema, H.; DeHaven, D. L. SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur. J. Pharmacol. 1984, 101, 159-160.
9. Christensen, A. V.; Arnst, J.; Hyttel, J.; Larsen, J. J.; Svendsen, O. Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci. 1984,34, 1529-1540.
10. Clark, D.; White, F. J.; Review: Di dopamine receptor-The Search for a Function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1987, 1, 347-388.
11. Robertson, H. A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci. 1992, 15, 201-206.
12. Anderson, J.; Gingrich, J.; Bates, M.; Dearry, A.; Faladeau, P.; Senogles, S.; Caron, M. Dopamine Receptor Subtypes: Beyond the D1/D2 Classification. Trends Pharmacol. Sci. 1990, 22, 231-236.
13. Zhou, Q.-Y.; Grandy, D.; Thambi, L.; Kushner, J.; Van Tol, H.; Cone, R.; Pribnow, D.; Salon, J.; Bunzow, J.; Civelli, O. Cloning and Expression of Human and Rat D] Dopamine Receptors. Nature 1990, 347, 76-80.
14. Dearry, A.; Gingrich, J. A.; Falardeau, P.; Fremeau, R. T.; Bates, M. D.; Caron, M. G. Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 1990, 347, 72-76.
15. Sunahara, R.; Niznik, H.; Weiner, D.; Stormann, T.; Brahn, M.; Kennedy, J.; Gelernter, J.; Yang, R.; Israel, Y.; Seeman, P.; O'Dowd, B. Human Dopamine D1 Receptor Encoded by an Intronless Gene on Chromosome 5. Nature 1990, 347, 80-83.
16. Monsma, F. J.; Mahan, L. C.; McVittie, L. D.; Gerfen, C. R.; Sibley, D. R. Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6723-6727.
17. Sunahara, R. K.; Gaun, H.-C.; O'Dowd, B. F.; Seeman, P.; Laurier, L. G.; Ng, G.; George, S. R.; Torichia, J.; Van Tol, H. H. M.; Niznik, H. B. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991, 350, 614-619.
18. Tiberi, M.; Jarvie, K. R.; Silvia, C.; Falardeau, P.; Gingrich, J. A.; Godinot, N.; Bertrand, L.; Yang-Fang, T. L.; Fremeau, R. T.; Caron, M. G. Cloning, molecular characterization and chromosomal assignment of a gene encoding a second D1 dopamine receptor subtype: differential expression pattern in rat brain compared with the Dia receptor. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7491-7495.
19. Taylor, J. R.; Lawrence, M. S.; Redmond, D. E., Jr.; Elsworth, J. D.; Roth, R. H.; Nichols, D. E.; Mailman, R. B. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur. J. Pharmacol. 1991, 199, 389—391.
20. Charifson, P. S.; Wyrick, S. D.; Hoffman, A. J.; Simmons, R. M.; Bowen, J. P.; McDouglad, D. L.; Mailman, R. B. Synthesis and Pharmacological Characterization of 1-Phenyl-, 4-Phenyl-, and 1-Benzyl-1,2,3,4-tetrahydroisoquinolines as Dopamine receptor ligands. J. Med. Chem. 1988, 31, 1941-1946.
21. Charifson, P.; Wyrick, S.; Hoffman, A.; Simmons, R.; Bowen, J.; McDouglad, D.; Mailman, R. Conformational Analysis and Molecular Modeling of 1-Phenyl-, 4-Phenyl-, and 1-Benzyl-1, 2,3,4-tetrahydroisoquinolines as D1 Dopamine Receptor Ligands. J. Med. Chem. 1988, 31, 2050-2058.
22. Pettersson, I.; Liljefors, T.; Bogeso, K. Conformational Analysis and Structure-activity Relationships of Selective Dopamine D1 Receptor Agonists and Antagonists of the Benzazepine Series. J. Med. Chem. 1990, 33, 2197-2204.
23. Pettersson, I.; Gundertofte, K.; Palm, J.; Liljefors, T. A Study on the Contribution of the 1-Phenyl Substituent to the Molecular Electrostatic Potentials of Some Benzazepines in Relation to Selective Dopamine D1 Receptor Activity. J. Med. Chem. 1992, 35, 502-507.
24. Weinstock, J.; Oh, H. J.; DeBrosse, C. W.; Eggleston, D. S.; Wise, M.; Flaim, K. E.; Gessner, G. W.; Sawyer, J. L.; Kaiser, C. Synthesis, Conformation and Dopaminergic Activity of 5,6-Ethano-bridged Derivatives of Selective Dopaminergic 3-Benzazepines. J. Med. Chem. 1987, 30, 1303-1308.
25. Mottola, D. M.; Brewster, W. K.; Cook, L. L.; Nichols, D. E.; Mailman, R. B. Dihydrexidine, A Novel Full Efficacy D1 Dopamine Receptor Agonist. J. Pharmacol. Exp. Ther. 1992, 262,383-393.
26. Mottola, D. M.; Laiter, S.; Watts, V. J.; Tropsha, A.; Wyrick, S. D.; Nichols, D. E.; Mailman, R. B. Conformational Analysis of D1 Dopamine Receptor Agonists: Pharmacophore Assessment and Receptor Mapping. Mol. Pharmacol. Submitted.
27. Cramer, R.; Patterson, D.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
28. Fodor, G.; Gal, J.; Phillips, B. A. The Mechanism of the Bischler-Napieralski Reaction. Angew. Chem., Int. Ed. Engl. 1972, 11, 919-920.
29. Clarke, H. T.; Gillespie, H. B.; Weisshaus, S. Z. Methylation of Primary or Secondary Amines with Formaldehyde and Formic Acid: A Special Form of the Leuckart-Wallach Reaction. J. Am. Chem. Soc. 1933, 55, 4571-4587.
30. Gold, E. H.; Chang, W. K. U.S. Patent 4349472, Sept 14, 1982.
31. Vlaeminck, F.; DeCock, E.; Tourwe, D.; Van Binst, G. Synthesis and Conformation of 5,6,8,9-tetrahydro-13bH-dibenΣ[a,h]quinolizine and 5,6,8,9,14,14b-hexahydrobenzo[a]indolo[3,2-h]quinolizine. Heterocycles 1981, 15, 1213-1218.
32. Wyrick, S. D.; McDouglad, D. L.; Mailman, R. B. Multiple Tritium Labelling of (+)-7-Chloro-8-hydroxy-1-phenyl-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, SCH23390. J. Lab. Compd. Radiopharm. 1986, 23, 685-692.
33. Schulz, D. W.; Staples, L. J.; Mailman, R. B. SCH23390 Causes Persistant Antidopaminergic Effects in vivo: Evidence for Long Term Occupation of Receptors. Life Sci. 1985, 36, 1941-1948.
34. Allinger, N.; et al. MM2(87) software, Molecular Design, Ltd.
35. SYBYL Version 5.4, Tripos and Associates, St. Louis, MO, 1991.
36. StatView 512+ software package, Brain Power Inc., Calabasas, CA, 1986.